secwatch.observer — SEC 8-K summary
======================================

Issuer:     Metagenomi Therapeutics, Inc. (MGX)
CIK:        0001785279
Form:       8-K
Filed at:   2025-11-12T23:59:59+00:00
Accession:  0001193125-25-276135
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Metagenomi Q3: $184.1M cash, 25% workforce cut, CEO change, MGX-001 data positive
--------------------------------------------------------------------------------

- Cash, equivalents, and marketable securities $184.1M as of Sep 30, 2025; runway extended into Q4 2027.
- Workforce reduced by 25%; early discovery and platform research deprioritized.
- Jian Irish promoted to CEO; founder Brian Thomas remains on Board; Willard Dere named Board Chair.
- MGX-001 hemophilia A preclinical data: curative FVIII activity in NHPs at proposed clinical dose averaging 49%.
- Pre-IND meeting expected Q4 2025; IND/CTA submissions targeted for Q4 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1785279/000119312525276135/0001193125-25-276135-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1785279/000119312525276135/mgx-20251111.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-276135

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer